Home › Funds › Defilade Capital Management, L.P. › ABT
Defilade Capital Management, L.P. position in ABT
ABBOTT LABORATORIES · Health Care
Defilade Capital Management, L.P. reported holding 285,778 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$25.9M, representing 3.47% of its reported portfolio and ranking #11 among its reported holdings. Defilade Capital Management, L.P. first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s ABT position evolved
Defilade Capital Management, L.P. first disclosed a stake in ABT in Q2 2026 at 285,778 shares (US$25.9M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 285.78K | $25.93M | New |
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held ABT?
Defilade Capital Management, L.P. has disclosed ABT holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Defilade Capital Management, L.P.'s current position in ABT?
As of Q2 2026, Defilade Capital Management, L.P. holds 285.78K shares of ABT (ABBOTT LABORATORIES), valued at $25.93M, representing 3.47% of its reported portfolio and ranking #11.
Has Defilade Capital Management, L.P. been buying or selling ABT?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. newly opened its position in ABT.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.